A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06372865 In Subjects Aged 18-55 (Group 1) And 56-75 Years (Group 2)

Trial Profile

A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06372865 In Subjects Aged 18-55 (Group 1) And 56-75 Years (Group 2)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs PF 6372865 (Primary)
  • Indications Pain
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Apr 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top